ClinicalTrials.gg
CompletedNCT00409175Updated Dec 17, 2012Results posted

Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis

A Phase 2/3 interventional study of Fx-1006A and Placebo in Familial Amyloid Polyneuropathy, sponsored by Pfizer. Completed at 10 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-12-17.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal — 4 open to participants now, 5 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Portugal.

Enrollment
8th of 10
128 · median 192
Started
2007
the only one that year
Phase 2/3
3 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
2 of 13
Pfizer

Among the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2/3, and was the 1st registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

4 of the 13 studies in Amyloid Neuropathies, Familial with a site in Portugal are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Amyloid Neuropathies, Familial with a site in Portugal, or all of them as a file.
02

Study summary

This study will examine whether Fx-1006A is effective in halting the progression of Familial Amyloid Polyneuropathy (FAP).

Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.

The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.

This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.

Read the detailed description

Deposition of TTR amyloid is associated with a variety of human diseases. Deposition of amyloid fibrils of variant TTR (primarily V30M) in peripheral nerve tissue produces the condition called FAP.

The prevention of the formation of amyloid by stabilization of the TTR native state should constitute an effective therapy for amyloid diseases. Therapeutic intervention with a TTR stabilizer drug, such as Fx-1006A, is hypothesized to stop progression of the disease in FAP patients. FAP is a uniformly fatal disease and Fx-1006A is intended to halt the relentless neurological deterioration FAP patients experience.

This Phase 2/3 study will enroll early to mid-stage FAP patients in order to interrupt and stabilize the disease at a point in time where progression of motor and autonomic dysfunction can be maximally effected. Male and female patients with FAP with documented V30M TTR mutation will receive Fx-1006A or placebo once daily for a period of eighteen (18) months.

03

Conditions studied

  • Familial Amyloid Polyneuropathy

Keywords

  • FAP
  • Fx-1006A
  • transthyretin
  • TTR
  • amyloid
  • polyneuropathy
  • V30M
  • familial
  • hereditary
  • amyloidosis
  • FoldRx
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Amyloid documented by .
  2. Documented V30M TTR mutation.
  3. Peripheral and/or autonomic neuropathy with a Performance Status ≥50.
  4. Patient is 18-75 years old.
  5. If female, patient is , surgically sterilized, or willing to use an acceptable method of . If male with a female partner of , willing to use an acceptable method of birth control for the duration of the study. For both females and males, birth control must be used for at least 3 months after the last dose of study medication.
  6. Patient is, in the opinion of the investigator, willing and able to comply with the study medication regimen and all other study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs).
  2. Primary amyloidosis.
  3. If female, patient is pregnant or breast feeding.
  4. Prior liver transplantation.
  5. No recordable sensory threshold for vibration perception in both feet, as measured by CASE IV.
  6. Positive results for surface antigen (HBsAg), anti- virus (HCV), and/or (HIV).
  7. Renal insufficiency or liver function test abnormalities.
  8. (NYHA) Functional Classification ≥III.
  9. Other causes of sensorimotor neuropathy (B12 deficiency, Diabetes Mellitus, HIV treated with retroviral medications, thyroid disorders, alcohol abuse, and chronic inflammatory diseases).
  10. Co-morbidity anticipated to limit survival to less than 18 months.
  11. Patient received an drug/device and/or participated in another clinical investigational study within 60 days before Baseline.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
128 participants (actual)

Study arms

  • Experimental
    1.

    Fx-1006A

    Drug: Fx-1006A

  • Placebo comparator
    2.

    Placebo

    Drug: Placebo

Interventions

  • Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

  • DrugPlacebo

    Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18

    Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than\[\<\] 2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.

    Time frame: Month 18

  2. Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18

    Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Month 18

Secondary outcomes

  1. Change From Baseline in Neuropathy Impairment Score- Lower Limb (NIS-LL) Score at Month 6, 12 and 18

    NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.

    Time frame: Baseline, Month 6, 12, 18

  2. Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 and 12

    Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to \<2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0 (normal) to 4 (paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.

    Time frame: Month 6, 12

  3. Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6 and 12

    Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

    Time frame: Baseline, Month 6, 12

  4. Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, 12 and 18

    Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale: 0=no problem, 4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment, for each. Total score=-2 to138(higher score=worse QOL).

    Time frame: Baseline, Month 6, 12, 18

  5. Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6, 12 and 18

    Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.

    Time frame: Baseline, Month 6, 12, 18

  6. Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6, 12 and 18

    Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.

    Time frame: Baseline, Month 6, 12, 18

  7. Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, 12 and 18

    BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation associated with malnutrition. A progressive decline in mBMI indicated worsening of disease severity.

    Time frame: Baseline, Month 6, 12, 18

  8. Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer

    TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

    Time frame: Week 8, Month 6, 12, 18

07

Results

Posted Dec 17, 2012
Limitations and caveats
Instead of the intended endpoint 'heat pain and cooling threshold', results of 'summated 3 score for small nerve fiber function' were reported.

Participant flow

Participant flow — Overall Study
MilestoneTafamidisPlacebo
Started6563
Completed4744
Not completed1819
Withdrew: Adverse event43
Withdrew: Withdrawal by subject12
Withdrew: Negative genotype01
Withdrew: Liver transplantation1313

Outcome measures

PrimaryPercentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18

Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than\[\<\] 2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.

Time frame:
Month 18
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 18
percentage of participantsTafamidisPlacebo
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 1845.3 (33.1 to 57.5)29.5 (18.1 to 41.0)
PrimaryChange From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18

Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Month 18
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life- Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 18
units on a scaleTafamidisPlacebo
Baseline27.3 ± 24.230.8 ± 26.7
Change at Month 182.4 ± 14.66.9 ± 22.9
SecondaryChange From Baseline in Neuropathy Impairment Score- Lower Limb (NIS-LL) Score at Month 6, 12 and 18

NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.

Time frame:
Baseline, Month 6, 12, 18
Reported as:
Mean · units on a scale
Change From Baseline in Neuropathy Impairment Score- Lower Limb (NIS-LL) Score at Month 6, 12 and 18
units on a scaleTafamidisPlacebo
Baseline (n=64, 61)8.359 ± 11.39911.445 ± 13.544
Change at Month 6 (n=60, 57)1.260 ± 3.0072.075 ± 6.407
Change at Month 12 (n=49, 50)1.005 ± 3.9644.835 ± 7.697
Change at Month 18 (n=48, 47)2.193 ± 4.3725.402 ± 8.661
SecondaryPercentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 and 12

Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to \<2) in NIS-LL score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0 (normal) to 4 (paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.

Time frame:
Month 6, 12
Reported as:
Number · percentage of participants
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6 and 12
percentage of participantsTafamidisPlacebo
Month 660.9 (49.0 to 72.9)54.1 (41.6 to 66.6)
Month 1254.7 (42.5 to 66.9)32.8 (21.0 to 44.6)
SecondaryChange From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6 and 12

Norfolk QOL-DN: 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on the quality of life of participants with diabetic neuropathy; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). TQOL= sum of all the items, total possible score range= -2 to 138, where higher score=worse quality of life.

Time frame:
Baseline, Month 6, 12
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Quality of Life (TQOL) Score at Month 6 and 12
units on a scaleTafamidisPlacebo
Baseline (n=64, 61)27.3 ± 24.230.8 ± 26.7
Change at Month 6 (n=60, 57)1.2 ± 15.60.2 ± 15.1
Change at Month 12 (n=49, 50)1.1 ± 14.74.6 ± 19.0
SecondaryChange From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, 12 and 18

Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7:scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale: 0=no problem, 4=severe problem (except item 32: -2=much better, 0=about same, 2=much worse). Norfolk QOL-DN summarized in 5 domains(score range):physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptoms(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12); higher score=greater impairment, for each. Total score=-2 to138(higher score=worse QOL).

Time frame:
Baseline, Month 6, 12, 18
Reported as:
Mean · units on a scale
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, 12 and 18
units on a scaleTafamidisPlacebo
Baseline: physical functioning(n=64,61)14.3 ± 13.816.6 ± 14.7
Baseline: ADLs(n=64,61)1.3 ± 2.91.6 ± 3.8
Baseline: symptoms(n=64,61)7.2 ± 5.57.6 ± 6.1
Baseline: small fiber neuropathy(n=64,61)2.7 ± 3.63.1 ± 4.0
Baseline: autonomic neuropathy(n=64,61)1.9 ± 2.42.0 ± 2.6
Change at Month 6: physical functioning(n=60,57)-0.6 ± 8.0-0.9 ± 9.8
Change at Month 6: ADLs(n=60,57)0.4 ± 1.90.3 ± 1.7
Change at Month 6: symptoms(n=60,56)0.8 ± 5.50.2 ± 4.4
Change at Month 6: small fiber neuropathy(n=60,57)0.4 ± 2.20.5 ± 2.5
Change at Month 6: autonomic neuropathy(n=60,57)0.2 ± 1.80.0 ± 1.7
Change at Month 12: physical functioning(n=49,50)-0.9 ± 7.40.6 ± 10.7
Change at Month 12: ADLs(n=49,50)1.0 ± 2.40.7 ± 3.0
Change at Month 12: symptoms(n=49,49)0.4 ± 5.01.4 ± 4.5
Change at Month 12:small fiber neuropathy(n=49,50)0.7 ± 2.81.5 ± 3.1
Change at Month 12: autonomic neuropathy(n=49,50)-0.1 ± 1.80.4 ± 2.8
Change at Month 18: physical functioning(n=48,47)-0.1 ± 8.53.0 ± 14.0
Change at Month 18: ADLs(n=48,47)1.2 ± 2.41.2 ± 4.2
Change at Month 18: symptoms(n=48,47)-0.1 ± 4.91.2 ± 5.4
Change at Month 18:small fiber neuropathy(n=48,47)0.8 ± 2.61.4 ± 3.6
Change at Month 18: autonomic neuropathy(n=48,47)0.2 ± 1.90.4 ± 2.8
SecondaryChange From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6, 12 and 18

Summated 7 score: composite score included five Nerve Conduction Studies (NCS) attributes (peroneal nerve distal motor latency, peroneal nerve compound muscle action potential, peroneal nerve motor conduction velocity, tibial nerve distal motor latency, and sural nerve sensory nerve action potential amplitude) along with Vibration Detection Threshold (VDT) obtained in great toes, and Heart Rate Response to Deep Breathing (HRDB) value. Score was determined through reference to normal values for age, sex and height. Total score range= -26 to 26, where higher score=worse nerve function.

Time frame:
Baseline, Month 6, 12, 18
Reported as:
Mean · units on a scale
Change From Baseline in Summated 7 Score for Large Nerve Fiber Function at Month 6, 12 and 18
units on a scaleTafamidisPlacebo
Baseline (n=64, 61)7.787 ± 9.0638.718 ± 8.533
Change at Month 6 (n=60, 57)0.581 ± 3.5421.934 ± 3.846
Change at Month 12 (n=48, 50)0.833 ± 3.9632.959 ± 3.879
Change at Month 18 (n=48, 46)1.159 ± 3.8533.333 ± 4.997
SecondaryChange From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6, 12 and 18

Summated 3 Nerve Tests Small Fiber Normal Deviates Score (NTSFnds) included cooling threshold for the lower limbs, heat pain threshold for the lower limbs and HRDB. Total score range= -11.2 to 11.2, where higher score=worse nerve function.

Time frame:
Baseline, Month 6, 12, 18
Reported as:
Mean · units on a scale
Change From Baseline in Summated 3 Score for Small Nerve Fiber Function at Month 6, 12 and 18
units on a scaleTafamidisPlacebo
Baseline (n=64, 61)5.514 ± 4.5355.624 ± 4.085
Change at Month 6 (n=60, 57)0.240 ± 1.6790.716 ± 2.202
Change at Month 12 (n=48, 50)0.375 ± 2.0481.250 ± 2.010
Change at Month 18 (n=48, 46)0.290 ± 2.1301.489 ± 2.519
SecondaryChange From Baseline in Modified Body Mass Index (mBMI) at Month 6, 12 and 18

BMI was calculated by weight divided by height squared. mBMI was calculated by multiplying BMI by serum albumin levels to compensate for edema formation associated with malnutrition. A progressive decline in mBMI indicated worsening of disease severity.

Time frame:
Baseline, Month 6, 12, 18
Reported as:
Mean · (kilogram/square meter)*(gram/liter)
Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, 12 and 18
(kilogram/square meter)*(gram/liter)TafamidisPlacebo
Baseline (n=64, 61)1004.6 ± 165.21011.5 ± 212.9
Change at Month 6 (n=60, 56)17.1 ± 68.4-29.8 ± 69.7
Change at Month 12 (n=49, 50)19.4 ± 71.8-30.8 ± 74.9
Change at Month 18 (n=49, 46)37.9 ± 73.7-32.7 ± 88.6
SecondaryPercentage of Participants With Stabilized Transthyretin (TTR) Tetramer

TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.

Time frame:
Week 8, Month 6, 12, 18
Reported as:
Number · percentage of participants
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
percentage of participantsTafamidisPlacebo
Week 8 (n=63, 60)98.4 (95.3 to 100.0)6.7 (0.4 to 13.0)
Month 6 (n= 59, 58)100.0 (100.0 to 100.0)5.2 (0.0 to 10.9)
Month 12 (n=48, 50)97.9 (93.9 to 100.0)2.0 (0.0 to 5.9)
Month 18 (n=48, 44)97.9 (93.9 to 100.0)0.0 (0.0 to 0.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tafamidis—6/65 (9.2%)57/65 (87.7%)
Placebo—5/63 (7.9%)56/63 (88.9%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTafamidisPlacebo
Urinary tract infectionInfections and infestations2/650/63
AnaemiaBlood and lymphatic system disorders0/651/63
Cardiac amyloidosisCardiac disorders0/651/63
NauseaGastrointestinal disorders0/651/63
VomitingGastrointestinal disorders0/651/63
Catheter site phlebitisGeneral disorders0/651/63
Oedema peripheralGeneral disorders0/651/63
CellulitisInfections and infestations0/651/63
LymphangitisInfections and infestations0/651/63
Staphylococcal infectionInfections and infestations0/651/63
Most frequent other events
Showing 10 of 34
Most frequent other events
EventTafamidisPlacebo
DiarrhoeaGastrointestinal disorders17/6511/63
Urinary tract infectionInfections and infestations14/658/63
HeadacheNervous system disorders10/6512/63
NeuralgiaNervous system disorders2/6512/63
Pain in extremityMusculoskeletal and connective tissue disorders11/656/63
ParaesthesiaNervous system disorders3/6510/63
InfluenzaInfections and infestations10/659/63
NasopharyngitisInfections and infestations9/658/63
NauseaGastrointestinal disorders8/658/63
Oedema peripheralGeneral disorders4/658/63

Baseline characteristics

Age, Customized
Age, Customized(participants)TafamidisPlaceboTotal
Less than or equal to 65 years5958117
Greater than 65 years538
Sex: Female, Male
Sex: Female, Male(Participants)TafamidisPlaceboTotal
Female323567
Male322658
08

Study locations

10 sites
  • MGH Neuropathy Laboratory
    Boston, Massachusetts 02114, United States
  • FLENI-Hepatology and Organ Transplant Dept.
    Ciudad de Buenos Aires, Buenos Aires Province C1428AQK, Argentina
  • Hospital Universitário Prof. Clementino Fraga Filho-UFRJ
    Rio de Janeiro, Southeast Cep 21945-560, Brazil
  • CHU de Bicetre
    Le Kremlin Bicêtre, Ile de France 94275, France
  • Universitatsklinikum Munster, Transplant Hepatology
    Munster, Nordrhein-Westfalen 48149, Germany
  • Serviço de Neurologia-Hospital de Santa Maria
    Lisboa, Lisbon 1649-035, Portugal
  • Unidade Clinica de Paramiloidose-Hospital Santo Antonio
    Porto, Norte 4099-001, Portugal
  • Hospital Clinic de Barcelona
    Barcelona, Catalunya 08036, Spain
  • Umea University Hospital
    Umea, Vasterbotten County SE-901 85, Sweden
  • Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years. Neurol Ther. 2020 Jun;9(1):105-115. doi: 10.1007/s40120-020-00180-w. Epub 2020 Feb 27. PubMed 32107748 ↗
  • Huber P, Flynn A, Sultan MB, Li H, Rill D, Ebede B, Gundapaneni B, Schwartz JH. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid. 2019 Dec;26(4):203-209. doi: 10.1080/13506129.2019.1643714. Epub 2019 Jul 27. PubMed 31353964 ↗
  • Amass L, Li H, Gundapaneni BK, Schwartz JH, Keohane DJ. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J Rare Dis. 2018 Dec 17;13(1):225. doi: 10.1186/s13023-018-0947-7. PubMed 30558645 ↗
  • Gundapaneni BK, Sultan MB, Keohane DJ, Schwartz JH. Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy. Eur J Neurol. 2018 Mar;25(3):464-468. doi: 10.1111/ene.13510. Epub 2017 Dec 26. PubMed 29115008 ↗
  • Keohane D, Schwartz J, Gundapaneni B, Stewart M, Amass L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid. 2017 Mar;24(1):30-36. doi: 10.1080/13506129.2017.1301419. Epub 2017 Apr 10. PubMed 28393570 ↗
  • Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid. 2016 Sep;23(3):178-183. doi: 10.1080/13506129.2016.1207163. Epub 2016 Aug 5. PubMed 27494299 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 3 years 7 months after primary completion. A results delay was requested in Mar 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2006
First posted
Dec 8, 2006
Start
Jan 2007
Primary completionActual
May 2009
CompletionActual
May 2009
Results delay requested
Mar 9, 2010
Results first posted
Dec 17, 2012
Last update
Dec 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00409175
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 8, 2006
Start date
Jan 2007
Primary completion
May 2009
Completion
May 2009
Results posted
Dec 17, 2012
Last update
Dec 17, 2012

Study contacts

Jeff Packman
study director · FoldRx Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafamidis

Start the discussion